2024
Opportunities in primary and enteric hyperoxaluria at the cross-roads between the clinic and laboratory
Cellini B, Baum M, Frishberg Y, Groothoff J, Harris P, Hulton S, Knauf F, Knight J, Lieske J, Lowther W, Moochhala S, Nazzal, Tasian G, Whittamore J, Sas D. Opportunities in primary and enteric hyperoxaluria at the cross-roads between the clinic and laboratory. Kidney International Reports 2024 DOI: 10.1016/j.ekir.2024.08.031.Peer-Reviewed Original ResearchInterleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor
Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro A, Rubenbauer L, Rao V, Burlein S, Genser B, Reichel M, Aronson P, Coca S, Knauf F. Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor. Scientific Reports 2024, 14: 11323. PMID: 38760468, PMCID: PMC11101424, DOI: 10.1038/s41598-024-61808-7.Peer-Reviewed Original ResearchConceptsIL-16 levelsIL-16Dialysis patientsCardiovascular eventsConcentrations of IL-16Kidney failureUremic toxinsCardiovascular diseaseCompared to healthy individualsPlasma oxalate concentrationActivated immune cellsAssociated with cardiovascular diseaseIL-16 concentrationCytokine IL-16Cardiovascular risk factorsNo significant associationPlasma oxalateInflammatory markersImmune cellsCytokine concentrationsInterleukin-16US patientsCohort 1Cardiovascular outcomesHealthy individuals
2022
Oxalate homeostasis
Ermer T, Nazzal L, Tio M, Waikar S, Aronson P, Knauf F. Oxalate homeostasis. Nature Reviews Nephrology 2022, 19: 123-138. PMID: 36329260, PMCID: PMC10278040, DOI: 10.1038/s41581-022-00643-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKidney diseaseOxalate homeostasisAnti-inflammatory medicationsChronic kidney diseaseKidney replacement therapySudden cardiac deathProgressive kidney diseaseOutlook of patientsOxalate nephropathyCardiovascular complicationsSystemic inflammationCardiac deathReplacement therapySecondary hyperoxaluriaKidney failureElevated plasmaConsequent impairmentNovel therapeuticsPatientsDiseaseEffective elimination strategiesEndogenous sourcesHomeostasisElimination strategyExcretion
2020
Pathophysiology and Treatment of Enteric Hyperoxaluria
Witting C, Langman C, Assimos D, Baum M, Kausz A, Milliner D, Tasian G, Worcester E, Allain M, West M, Knauf F, Lieske J. Pathophysiology and Treatment of Enteric Hyperoxaluria. Clinical Journal Of The American Society Of Nephrology 2020, 16: 487-495. PMID: 32900691, PMCID: PMC8011014, DOI: 10.2215/cjn.08000520.Peer-Reviewed Original ResearchConceptsEnteric hyperoxaluriaGastrointestinal disordersBariatric surgical proceduresCurrent therapeutic optionsAvailable treatment strategiesUrinary oxalate excretionKidney stone eventsLong-term efficacyKidney Health InitiativeNew therapeutic approachesComplicated obesityDietary modificationFat malabsorptionOxalate excretionTherapeutic optionsAdverse outcomesKidney failureStone eventsTreatment strategiesDietary oxalateSurgical proceduresTherapeutic approachesSevere casesHyperoxaluriaHealth initiatives
2019
P2X7 Receptor Stimulation Is Not Required for Oxalate Crystal-Induced Kidney Injury
Luz H, Reichel M, Unwin R, Mutig K, Najenson A, Tonner L, Eckardt K, Tam F, Knauf F. P2X7 Receptor Stimulation Is Not Required for Oxalate Crystal-Induced Kidney Injury. Scientific Reports 2019, 9: 20086. PMID: 31882798, PMCID: PMC6934555, DOI: 10.1038/s41598-019-56560-2.Peer-Reviewed Original ResearchConceptsIL-1ß releaseDendritic cellsKidney failureP2X7 receptorBone marrowNLRP3/CASPP2X7 receptor signalingProgressive kidney diseaseSuitable therapeutic targetProgressive kidney failureMonosodium urate crystalsHuman peripheral bloodKidney injuryRenal inflammationRenal injuryTubular damageWT miceIL-1ßKidney diseasePeripheral bloodCytokine releasePlasma creatinineMurine bone marrowInterleukin-1betaInflammasome activation